Hematuria Evaluation in Elderly Patients

Introduction to Hematuria Evaluation

The American College of Cardiology recommends considering temporary interruption of apixaban for 48 hours prior to elective procedures with moderate bleeding risk in patients with atrial fibrillation, and the patient's age and anticoagulation use warrant a thorough evaluation for recurrent hematuria 2
The patient's age (>80 years) requires consideration for reduced dosing of apixaban, with a recommended dose of 2.5 mg twice daily 2
The American Heart Association suggests that apixaban has a better safety profile compared to other anticoagulants, but the patient's recurrent hematuria despite antibiotics warrants further evaluation 3

A complete blood count, comprehensive metabolic panel, urinalysis with microscopy, and urine culture should be performed to assess for anemia, renal function, and to rule out persistent infection despite antibiotic treatment, with consideration of measuring apixaban levels if available (levels >50 ng/mL with serious bleeding may warrant reversal consideration) 1
Coagulation studies (PT/INR, aPTT) should be performed to evaluate the patient's bleeding risk, especially when considering temporary interruption of apixaban 1

Renal ultrasound is the first-line imaging study to evaluate for structural abnormalities, hydronephrosis, masses, or stones, with consideration of CT urography if ultrasound is non-diagnostic and renal function permits 1
For diagnostic procedures with bleeding risk, consider temporary interruption of apixaban for 48 hours, or reversal options such as andexanet alfa or four-factor prothrombin complex concentrate (PCC) if urgent evaluation is needed with significant bleeding 1

Urgent urology referral is warranted given the patient's age (>90 years), recurrent hematuria despite antibiotics, and anticoagulation use, with consideration of urologic malignancy, anticoagulant-related bleeding, urinary tract infection, and urolithiasis as potential causes of hematuria 2
After initial evaluation, coordinate care between cardiology and urology, and reassess anticoagulation strategy based on findings and bleeding risk, with consideration of dose adjustment based on weight and renal function 3

Attributing hematuria solely to anticoagulation is not recommended, as underlying pathology such as malignancy should always be ruled out, especially in elderly patients with recurrent hematuria 2
Prolonged interruption of anticoagulation increases stroke risk in atrial fibrillation, and inadequate evaluation due to age or comorbidities can lead to failure to diagnose underlying conditions such as urologic malignancy 3